Showing results (501-510 of 523) with videos related to
Sort By:
Pageof 53
Clinical Lung Cancer|December 17, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung CancerMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.Radiology|November 26, 2024
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with MetastasesLama Dawi, Younes Belkouchi, Littisha Lawrance, et al.Nature Medicine|February 4, 2022
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus ReportAnne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR TrialSolange Peters, Sarah Danson, Baktiar Hasan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2019
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung CancerGonzalo Recondo, Laura Mezquita, Francesco Facchinetti, et al.The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.Nature Medicine|February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trialBenjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer GroupMariana Brandão, Elena Prisciandaro, Eleni Xenophontos, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.Pageof 53